MESO

Mesoblast Limited [MESO] Stock Forecast

Q: What is Mesoblast Limited stock symbol ?

Mesoblast Limited is a AU stock, located in Melbourne of Vic and trading under the symbol MESO

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

MESO Stock Summary

EPS has been increasing for the past 3 years (Yearly statements)

Earnings are expected to fall -100% next year

Top 10 Correlated ETFs

MESO

Top 10 Correlated Stocks

MESO

In the News

MESO Financial details

Company Rating

Neutral

Market Cap

612.2M

Income

-81.89M

Revenue

7.5M

Book val./share

Cash/share

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

28 Aug 2024

P/E

-1.84

Forward P/E

PEG

0.66

P/S

26.79

P/B

0.3

P/C

P/FCF

-3.16

Quick Ratio

1.86

Current Ratio

1.95

Debt / Equity

LT Debt / Equity

0.21

EPS (TTM)

-0.96

EPS next Y

EPS next Q

EPS this Y

-21.05%

EPS next Y

EPS next 5Y

EPS last 5Y

-9.4%

Revenue last 5Y

-14.81%

Revenue Q/Q

10.31%

EPS Q/Q

16.67%

SMA20

150%

SMA50

150%

SMA100

66.67%

Inst Own

0.79%

Inst Trans

0.68%

ROA

-12%

ROE

-16%

ROC

-0.11%

Gross Margin

97%

Oper. Margin

-935%

Profit Margin

-1092%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

1.61-10.24

52W High

-47.4%

52W Low

+426%

RSI

Rel Volume

0.02

Avg Volume

2.29M

Volume

52.94K

Perf Week

-8.2%

Perf Month

144.65%

Perf Quarter

124.79%

Perf Half Y

121.01%

Beta

2.593

Volatility

0.2%, 1.58%

Prev Close

2.94%

Price

5.26

Change

6.26%

MESO Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-06-30

Metric	2019-06-30	2020-06-30	2021-06-30	2022-06-30	2023-06-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.32	0.58	0.12	0.15	0.1
Net income per share	-1.72	-1.4	-1.55	-1.33	-1.05
Operating cash flow per share	-1.11	-1.01	-1.67	-0.96	-0.81
Free cash flow per share	-1.11	-1.05	-1.7	-0.96	-0.82
Cash per share	0.97	2.32	2.14	0.88	0.91
Book value per share	9.23	9.85	9.11	7.26	6.44
Tangible book value per share	-1.96	-0.58	0.01	-1.19	-0.97
Share holders equity per share	9.23	9.85	9.11	7.26	6.44
Interest debt per share	1.78	2.02	1.82	1.81	1.74
Market cap	526.63M	1.27B	954.68M	303.87M	609.53M
Enterprise value	557.49M	1.24B	923.29M	350.74M	655.11M
P/E ratio	-5.86	-16.3	-9.66	-3.33	-7.44
Price to sales ratio	31.49	39.51	128.04	29.76	81.26
POCF ratio	-9.11	-22.54	-8.95	-4.62	-9.63
PFCF ratio	-9.07	-21.68	-8.81	-4.6	-9.59
P/B Ratio	1.09	2.31	1.64	0.61	1.21
PTB ratio	1.09	2.31	1.64	0.61	1.21
EV to sales	33.34	38.58	123.83	34.35	87.34
Enterprise value over EBITDA	-6.87	-16.45	-8.58	-4.58	-10.07
EV to operating cash flow	-9.65	-22.01	-8.65	-5.33	-10.35
EV to free cash flow	-9.6	-21.17	-8.52	-5.31	-10.3
Earnings yield	-0.17	-0.06	-0.1	-0.3	-0.13
Free cash flow yield	-0.11	-0.05	-0.11	-0.22	-0.1
Debt to equity	0.17	0.18	0.18	0.22	0.23
Debt to assets	0.12	0.14	0.14	0.16	0.17
Net debt to EBITDA	-0.38	0.4	0.29	-0.61	-0.7
Current ratio	1.41	1.51	1.57	1.36	1.95
Interest coverage	-7.35	-5.93	-10.44	-4.79	-3.56
Income quality	0.64	0.72	1.08	0.72	0.77
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	1.29	0.8	4.14	2.66	3.38
Research and developement to revenue	3.58	1.75	7.11	3.21	3.62
Intangibles to total assets	0.89	0.79	0.78	0.87	0.86
Capex to operating cash flow	0	0.04	0.02	0	0
Capex to revenue	-0.02	-0.07	-0.22	-0.02	-0.04
Capex to depreciation	-0.13	-0.61	-0.39	-0.05	-0.08
Stock based compensation to revenue	0.26	0.23	1.68	0.54	0.49
Graham number	18.91	17.6	17.82	14.77	12.34
ROIC	-0.13	-0.11	-0.16	-0.13	-0.11
Return on tangible assets	-1.3	-0.51	-0.6	-1.09	-0.89
Graham Net	-2.29	-0.98	-0.4	-1.49	-1.17
Working capital	18.19M	46.41M	53.95M	18.46M	39.68M
Tangible asset value	-102.07M	-32.28M	851K	-81.61M	-75.35M
Net current asset value	-108.54M	-47.73M	-15.09M	-95.26M	-85.92M
Invested capital	0.17	0.18	0.18	0.22	0.23
Average receivables	27.21M	2.82M	3.21M	4.62M	5.7M
Average payables	15.99M	19.02M	22.29M	21.34M	21.61M
Average inventory	-2.03M	-2.82M	-3.21M	-2.42M	199K
Days sales outstanding	88.62	17.87	237.03	157.39	340.52
Days payables outstanding	310.39	360.14	218.63	273.88	265.13
Days of inventory on hand	-96.49	-22.7	-54.02	0	5.24
Receivables turnover	4.12	20.43	1.54	2.32	1.07
Payables turnover	1.18	1.01	1.67	1.33	1.38
Inventory turnover	-3.78	-16.08	-6.76	0	69.68
ROE	-0.19	-0.14	-0.17	-0.18	-0.16
Capex per share	-0.01	-0.04	-0.03	0	0

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q1

Metric	2022-09-30	2022-12-31	2023-03-31	2023-06-30	2023-09-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.01	0.03	0.02	0.03	0
Net income per share	-0.12	-0.32	-0.24	-0.28	0
Operating cash flow per share	-0.1	-0.21	-0.21	-0.21	0
Free cash flow per share	-0.1	-0.21	-0.21	-0.21	0
Cash per share	0.61	0.87	0.63	0.9	0
Book value per share	3.76	6.44	6.21	6.38	0
Tangible book value per share	-0.4	-1	-1.23	-0.96	0
Share holders equity per share	3.76	6.44	6.21	6.38	0
Interest debt per share	0.82	1.5	1.54	1.53	0
Market cap	709.99M	452.13M	511.17M	615.16M	0
Enterprise value	734.51M	496.7M	577.39M	660.73M	0
P/E ratio	-10.51	-4.62	-6.87	-7.02	0
Price to sales ratio	492.03	228.35	263.63	287.59	0
POCF ratio	-49.7	-27.48	-31.46	-37.79	0
PFCF ratio	-49	-27.42	-31.38	-37.71	0
P/B Ratio	1.36	0.9	1.06	1.23	0
PTB ratio	1.36	0.9	1.06	1.23	0
EV to sales	509.02	250.86	297.78	308.9	0
Enterprise value over EBITDA	-49.3	-24.8	-42.86	-37.42	0
EV to operating cash flow	-51.41	-30.19	-35.53	-40.59	0
EV to free cash flow	-50.69	-30.12	-35.44	-40.5	0
Earnings yield	-0.02	-0.05	-0.04	-0.04	0
Free cash flow yield	-0.02	-0.04	-0.03	-0.03	0
Debt to equity	0.21	0.22	0.24	0.23	0
Debt to assets	0.16	0.17	0.18	0.17	0
Net debt to EBITDA	-1.65	-2.23	-4.91	-2.58	0
Current ratio	1.9	1.43	1.14	1.95	0
Interest coverage	-3.52	-4.31	-2.9	-4.92	0
Income quality	0.85	0.67	0.87	0.74	0
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	4.78	3.23	3.3	2.66	0
Research and developement to revenue	3.98	3.88	3.64	3.13	0
Intangibles to total assets	0.84	0.87	0.89	0.86	0
Capex to operating cash flow	0.01	0	0	0	0.01
Capex to revenue	-0.14	-0.02	-0.02	-0.02	0
Capex to depreciation	-0.18	-0.03	-0.04	-0.04	0
Stock based compensation to revenue	0.24	0.71	0.41	0.52	0
Graham number	3.2	6.76	5.78	6.32	0
ROIC	-0.02	-0.03	-0.02	-0.03	0
Return on tangible assets	-0.16	-0.27	-0.26	-0.24	0
Graham Net	-0.53	-1.22	-1.44	-1.16	0
Working capital	44.16M	23.56M	7.45M	39.68M	0
Tangible asset value	-55.47M	-77.9M	-95.36M	-75.35M	0
Net current asset value	-68.73M	-89.93M	-106.91M	-85.92M	0
Invested capital	0.21	0.22	0.24	0.23	0
Average receivables	4.13M	4.04M	5.7M	7.09M	0
Average payables	20.37M	20.33M	21.98M	20.56M	0
Average inventory	0.5	2.9M	5.19M	2.49M	0
Days sales outstanding	240.94	191.86	333.36	294.45	0
Days payables outstanding	326.69	8.24K	302.19	207.75	0
Days of inventory on hand	0	2.08K	65.94	4.1	0
Receivables turnover	0.37	0.47	0.27	0.31	0
Payables turnover	0.28	0.01	0.3	0.43	0
Inventory turnover	4.87M	0.04	1.36	21.93	0
ROE	-0.03	-0.05	-0.04	-0.04	0
Capex per share	0	0	0	0	0

MESO Frequently Asked Questions

What is Mesoblast Limited stock symbol ?

Mesoblast Limited is a AU stock , located in Melbourne of Vic and trading under the symbol MESO

What is Mesoblast Limited stock quote today ?

Mesoblast Limited stock price is $5.26 today.

Is Mesoblast Limited stock public?

Yes, Mesoblast Limited is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 2.29M
Market Capitalization 612.2M
Employee 83
CEO Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)
Headquarters Melbourne,VIC,AU
IPO Date 2010-01-20
Website https://www.mesoblast.com

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.